Related Experiment Video

Updated: May 18, 2026

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile

Hugo A Farne1, Natasha K Martin, Janice Main

  • 1Queen Elizabeth Hospital, University of Bristol, Bristol, UK. hugo.farne@gmail.com

European Journal of Gastroenterology & Hepatology
|October 3, 2012
PubMed
Abstract

Insights

C-reactive protein (CRP) effectively predicts metronidazole treatment failure in Clostridium difficile infection. Higher CRP levels indicate a higher likelihood of treatment failure, guiding clinical decisions.

Area of Science:

  • Infectious Diseases
  • Clinical Microbiology
  • Biomarkers

Background:

  • Clostridium difficile infection (CDI) is a significant healthcare-associated infection.
  • Metronidazole is a common first-line treatment for mild-to-moderate CDI.
  • Predicting treatment failure is crucial for timely therapeutic adjustments.

Purpose of the Study:

  • To evaluate C-reactive protein (CRP) as a predictor of metronidazole treatment failure in CDI.
  • To compare CRP's predictive ability against other common clinical metrics.
  • To identify reliable indicators for metronidazole non-response in CDI patients.

Main Methods:

  • Retrospective review of 65 patients with CDI treated with metronidazole.
  • Patients categorized based on response to metronidazole (resolution within 6 days vs. need for vancomycin).
  • Statistical analysis including t-test, Kruskal-Wallis, Fisher's exact test, and logistic regression.

Main Results:

  • 74% of patients (48/65) responded to metronidazole alone.
  • Significantly higher C-reactive protein (CRP) levels were observed in patients who failed metronidazole treatment (P<0.01).
  • White cell count and creatinine levels also differed significantly between treatment success and failure groups.

Conclusions:

  • C-reactive protein (CRP) is a valuable predictor of metronidazole treatment failure in mild-to-moderate CDI.
  • CRP levels can aid clinicians in identifying patients likely to require alternative therapies.
  • Early identification of treatment failure improves patient outcomes in CDI management.

More Related Videos

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection09:12

A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection

Published on: June 15, 2018

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...